The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.
 
Yung-Jue Bang
Consulting or Advisory Role - BeiGene; Samyang
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Bayer; Lilly; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
 
Charles S. Fuchs
Consulting or Advisory Role - Agios; Bayer; Dicerna; Entrinsic Health; Five Prime Therapeutics; Genentech/Roche; Gilead Sciences; KEW; Lilly; Merck; Merrimack; Sanofi; Taiho Pharmaceutical
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Josep Tabernero
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Genentech/Roche; Lilly; Merck Serono; MSD; Novartis; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical
 
David H. Ilson
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly/ImClone; Merck; Pieris Pharmaceuticals; Roche/Genentech
 
Woo Jin Hyung
Stock and Other Ownership Interests - Hutom
Consulting or Advisory Role - Ethicon
Research Funding - Medtronic (Inst)
 
Vivian E. Strong
No Relationships to Disclose
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; Shire
Speakers' Bureau - Lilly
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly
 
Takaki Yoshikawa
Honoraria - Abbott Nutrition; Ajinomoto; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson; Lilly; Medtronic; Nihonkayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; MSD Oncology; Novartis
Research Funding - Chugai Pharma; Novartis; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Laura H. Tang
No Relationships to Disclose
 
Peggy May Tan Hwang
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Ono Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Lilly; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)